Solid tumour treatment developer Atreca has set a $100m target for an initial public offering that will provide GlaxoSmithKline with an exit.

Atreca, a US-based immunotherapy developer that counts pharmaceutical firm GlaxoSmithKline (GSK) as an investor, has filed for a $100m initial public offering on the Nasdaq Global Market. Founded in 2010, Atreca is working on immunotherapeutics intended to fight off solid tumours by using antibody-target pairs indicated by the immune systems of patients who respond successfully…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.